Connect with us


Merck KGaA says MS drug fails in late-stage trials



The logo of German pharmaceuticals company Merck is seen at the company’s headquarters in Darmstadt, Germany, May 16, 2016. REUTERS/Kai Pfaffenbach/File Photo Acquire Licensing Rights

FRANKFURT, Dec 5 (Reuters) – Germany’s Merck KGaA (MRCG.DE) said on Tuesday the company’s experimental multiple sclerosis drug evobrutinib did not meet the primary goal in highly anticipated late-stage trials.

Phase III trial results for the drug evobrutinib in relapsing multiple sclerosis did not meet the primary endpoint of reducing annualized relapse rates compared to Sanofi’s (SASY.PA) established pill Aubagio, Merck said in a statement.

Reporting by Ludwig Burger

Our Standards: The Thomson Reuters Trust Principles.

Acquire Licensing Rights, opens new tab
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *